In the News

GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease

GRAIL today announced a collaboration with global biopharmaceutical companies Amgen, AstraZeneca, and Bristol Myers Squibb to evaluate GRAIL’s methylation-based technology for the detection of minimal residual disease (MRD). Cancer MRD testing is used in clinical and research applications to detect the presence or absence of residual...

McKesson Ventures Expands Portfolio Development Team and Invests in Market Research

McKesson Ventures has added Lizzie Lee as its newest team member. She joins the firm as senior director, leading its portfolio development and market research efforts. With a decade of healthcare experience, Lee is well-positioned to help McKesson Ventures’ portfolio companies scale by developing and facilitating...

Aspen RxHealth Raises $23M Series B Funding Round Led by Bessemer Venture Partners

Aspen RxHealth, developer of a first-of-its-kind clinical pharmacy model developed by pharmacists for pharmacists that delivers value for health plans and risk-bearing providers, today announced the closure of a $23 million Series B funding round led by Bessemer Venture Partners, with participation from other strategic...

The Future of Care Demands a Virtual Health Ecosystem

Telehealth usage skyrocketed in the early stages of the COVID-19 pandemic. According to data from EHR vendor Epic Systems, telehealth visits peaked in mid-April, when telehealth accounted for 69 percent of all ambulatory care visits. Although the percentage dropped to 21 percent by mid-July, telehealth...

Is the COVID Vaccine the Shot in the Arm We Need for Healthcare Access?

Colin Hung recently interviewed Chris Gervais, CTO and CSO at Kyruus; and Pamela Landis, vice president of digital engagement at Hackensack Meridian Health, for a discussion of healthcare access and the importance of that access in light of the COVID-19 pandemic. Gervais began by saying that...

McKesson Ventures Invests as Clinical Ink Debuts Lunexis™ ePRO+ Solution

Clinical Ink, a global clinical trial technology company, today announced an investment from McKesson Ventures, along with its significantly enhanced electronic patient reported outcome (ePRO) module. “McKesson Ventures is excited to invest in Clinical Ink, a market leader in clinical trial enablement technology,” said Dave Schulte,...

Michelle Snyder, Digital Health Veteran, Joins McKesson Ventures

McKesson Ventures has hired Michelle Snyder as its newest investment partner. Snyder, a mobile health pioneer, is known for her leadership and guidance in building Epocrates, one of the healthcare industry’s first successful mobile health companies. She brings more than 25 years of healthcare experience to...